Serum adipocytokine profile and metabolic syndrome in young adult female dermatomyositis patients by Silva, Marilda Guimarães et al.
Serum adipocytokine profile and metabolic syndrome
in young adult female dermatomyositis patients
Marilda Guimara˜es Silva, Eduardo Ferreira Borba, Suzana Beatriz Verı´ssimo de Mello, Samuel Katsuyuki Shinjo*
Faculdade de Medicina da Universidade de Sa˜o Paulo, Clı´nica Me´dica, Reumatologia, Sa˜o Paulo/SP, Brazil.
OBJECTIVES: To analyse the frequency of metabolic syndrome in young adult female dermatomyositis
patients and its possible association with clinical and laboratory dermatomyositis-related features and serum
adipocytokines.
METHOD: This cross-sectional study included 35 dermatomyositis patients and 48 healthy controls. Metabolic
syndrome was defined according to the 2009 Joint Interim Statement.
RESULTS: Patient age was comparable in the dermatomyositis and control groups, and the median disease
duration was 1.0 year. An increased prevalence of metabolic syndrome was detected in the dermatomyositis
group (34.3% vs. 6.3%; p=0.001). In addition, increased serum adiponectin and resistin levels were noted in
contrast to lower leptin levels. In dermatomyositis patients, adipocytokine levels were correlated with the levels
of total cholesterol, low-density cholesterol, triglycerides and muscle enzymes. A comparison of dermatomyo-
sitis patients with (n=12) and without (n=23) syndrome metabolic revealed that adipocytokine levels were also
correlated with age, and that dermatomyositis patients with metabolic syndrome tended to have more disease
activity despite similar adipocytokine levels.
CONCLUSIONS: Metabolic syndrome is highly prevalent in young adult female dermatomyositis patients and is
related to age and disease activity. Moreover, increased serum adiponectin and resistin levels were detected in
dermatomyositis patients, but lower serum leptin levels were observed.
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’ INTRODUCTION
Adipose tissue is an endocrine organ that influences body
weight, glucose metabolism and lipid homeostasis (1,2), thus
affecting several parameters of metabolic syndrome (MetS).
In fact, MetS is characterized by an accumulation of condi-
tions that include central obesity, dyslipidaemia, arterial
hypertension and impaired glucose tolerance (3,4), which may
be associated with inflammatory status (5). The endocrine
influence of adipose tissue is determined by a group of active
peptides known as adipocytokines, which can be characterized
as having pro-inflammatory (e.g., leptin and resistin) or anti-
inflammatory (e.g., adiponectin) effects (6).
Adipocytokines have been described in different systemic
autoimmune diseases, such as systemic lupus erythaemato-
sus (7,8) and rheumatoid arthritis (9,10), but they have rarely
been studied in dermatomyositis (DM) (11,12). In one study,
similar serum adiponectin levels were detected in DM patients
and a control group, and the levels were related to pulmonary
involvement (11). In another report, high levels of serum resistin
were associated with DM inflammation, muscle injury and
an increased global disease activity index (12). In addition to
these findings, only two previous studies have assessed MetS
and the risk factors of cardiovascular diseases (CVD) in adult
patients with idiopathic inflammatory myopathies (13,14).
Of note, de Moraes et al. (13) observed a high frequency of
MetS (41.7%) in their DM cohort, likely due to the inclu-
sion of older patients, both genders and postmenopausal
women (13).
Thus, the present study aimed to evaluate the frequency of
MetS specifically in a cohort of young female DM patients
and to analyse the role of serum adipocytokines and their
association with clinical and laboratory data, DM disease
status and different aspects of MetS.
’ MATERIALS AND METHODS
This cross-sectional study was performed at a single centre
and included 35 consecutive female DM patients (age X18
andp45 years) enrolled from January 2012 to July 2014 who
fulfilled all of the Bohan and Peter criteria items (15) and
were regularly examined at our myopathy unit. Patients withDOI: 10.6061/clinics/2016(12)06
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clinically amyopathic DM, cancer-associated myositis, acute
and/or chronic infections, liver and renal diseases, meno-
pause or a body mass index (BMI)X30 kg/m2 were excluded.
Forty-eight age-, gender- and BMI-matched healthy volunteers
were recruited as a control group during the same period. The
local Ethics Committee approved the study.
All participants underwent a clinical evaluation that included
a standardized interview, and charts were extensively reviewed.
Demographic data included current age, household income
status (16), gender, ethnicity, waist circumference, weight and
BMI [weight/height2 (kg/m2)]. Clinical and laboratory data
included age at disease onset, disease duration and serum
levels of creatine phosphokinase, aldolase, alanine amino-
transferase, aspartate aminotransferase, lactate dehydrogen-
ase, fasting blood glucose, total cholesterol, high-density
(HDL) cholesterol, low-density (LDL) cholesterol and trigly-
cerides. These blood lipids were assessed in fasting serum
samples by spectrophotometry.
Disease status was evaluated by the following question-
naires and scores: global assessment of the disease
(by the physician and the patient) through the visual
analogue scale (VAS) (17,18), Manual Muscle Testing
(MMT-8) (19,20), Health Assessment Quality (HAQ) (19)
and Myositis Disease Activity Assessment Visual Analogue
Scales (MYOACT) (17).
Therapy data included the use of immunosuppressives,
immunomodulatory corticosteroids [current dose and cumu-
lative dose (since disease symptoms began)] and antimalarials.
The evaluation of comorbidities included the presence of
arterial hypertension, dyslipidaemia, type 2 diabetes melli-
tus, hypothyroidism, myocardium infarction and ischaemic
stroke. Dyslipidaemia was defined as having values of plasma
total cholesterol 4200 mg/dL, HDL cholesterol o40 mg/dL,
LDL cholesterol 4130 mg/dL, triglycerides 4150 mg/dL or
drug treatment for elevated LDL cholesterol or triglycerides (20).
Lifestyle evaluations of tobacco use, alcohol use, sedentary
lifestyle (21) and food habit alterations were also conducted.
Family history of CVD was evaluated, including myo-
cardial infarction, angina or sudden death in first-degree
relatives before age 65 for women.
Laboratory evaluation: A blood sample (5 mL of blood)
obtained from each participant after a 12-hour overnight fast
was collected and immediately (o30 min) centrifuged at
3000 rpm for 10 minutes at 4oC. The serum was stored at
-80oC until cytokine analysis (adiponectin, leptin and resistin)
was performed using the Luminex 200- xMAP Instrument
(Millipore, USA), as described elsewhere (22).
MetS was defined according to the 2009 Joint Interim
Statement (JIS) of the International Diabetes Federation,
National Heart, Lung, and Blood Institute, American Heart
Association, World Heart Federation, International Athero-
sclerosis Society and International Association for the Study of
Obesity (23). MetS was defined for DM patients and controls
according to the presence of three or more of the following
criteria: increased waist circumference (X80 cm for South
American women); increased triglycerides (X150 mg/dL) (drug
treatment for elevated triglycerides was an alternate indicator);
reduced HDL-cholesterol (o50 mg/dL) (drug treatment for
reduced HDL cholesterol was an alternate indicator); increased
blood pressure (systolic pressureX130 mmHg and/or diastolic
X85 mmHg) (antihypertensive drug treatment in patients with
a history of hypertension was an alternative indicator); and
increased fasting glucose (X100 mg/d) (drug treatment of
increased glucose was an alternate indicator).
CVD and its risk factors included the presence of coronary
heart disease, cerebrovascular disease (for example, ischae-
mic stroke), deep vein thrombosis and pulmonary embolism,
systemic arterial hypertension, diabetes mellitus, smoking,
sedentary lifestyle, alcohol consumption and/or dyslipidaemia.
Statistical analysis: The Kolmogorov-Smirnov test was
used to evaluate the distribution of each parameter. The
demographic and clinical features were expressed as the
means±standard deviations (SD) for continuous variables or
as frequencies and percentages (%) for categorical variables.
The median (25th-75th interquartile range) was calculated for
continuous variables that were non-normally distributed.
Comparisons between the patient and control parameters
were made using Student’s t-test or the Mann-Whitney test
for continuous variables, and the chi-squared test or Fisher’s
exact test were used to evaluate categorical variables. The
correlations among the parameters were analysed by Spear-
man correlation. All analyses were performed using SPSS
15.0 statistical software (Chicago, USA). A value of po0.05
was considered to indicate statistical significance.
’ RESULTS
Thirty-five DM patients and 48 controls were evaluated.
The mean age, BMI and weight and the frequencies of eth-
nicities and socioeconomic status were comparable between
both groups (Table 1). The mean age at disease onset was
28.4 years, with a five-month period of symptoms prior to
diagnosis and a median disease duration of 1.0 year. As
expected, all muscle enzymes were significantly increased
in DM patients. The main disease status parameters are
presented in Table 1.
Two-thirds of the DM patients were using therapy, with a
total cumulative dose of prednisone of 15.40 g. Eight patients
(22.9%) were also using an antimalarial [chloroquine dipho-
sphate (250 mg/day) or hydroxychloroquine sulphate
(400 mg/day)]. Approximately half of the patients were
using at least one immunosuppressive or immunomodula-
tory drug: azathioprine (2-3 mg/kg/day), methotrexate
(15-25 mg/week), cyclosporine (1.5-2.5 mg/kg/day), myco-
phenolate mofetil (2-3 g/day), rituximab [1 g, intravenous, at
baseline and after one month (first cycle) and this schema
was repeated after six months], cyclophosphamide (0.8 g/m2
body surface), leflunomide (20 mg/day) and/or intravenous
human immunoglobulin (2 g/kg, daily, two consecutive
days) (Table 1).
An increased frequency of MetS was detected in DM
patients compared to controls (34.3% vs. 6.3%; p=0.001)
(Table 2). The abdominal circumference, which is a part of
the MetS criteria, was also increased in DM patients
compared to the control group (po0.001).
No difference was observed between groups regarding
comorbidities, lifestyle or family history of CVD, with the
exception of diabetes mellitus [present only in DM patients
(2.9%)] and tobacco use [present only in the control group
(6.3%)]. No cases of ischaemic stroke, myocardial infarction
or alcohol consumption were included in either group.
Regarding the laboratory parameters, both groups had
similar fasting blood glucose, total cholesterol and LDL
cholesterol levels. However, higher serum levels of HDL
cholesterol and leptin were detected in controls, whereas
higher serum levels of LDL cholesterol, triglycerides, insulin,
adiponectin and resistin levels were identified in DM
patients.
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A further analysis of DM patients revealed that the serum
level of adiponectin was moderately correlated with the
levels of total cholesterol (rho=0.444; p=0.014) and LDL
cholesterol (rho=0.443; p=0.014) and that the level of resistin
was correlated with that of triglycerides (rho=0.400;
p=0.029). The leptin level was negatively associated with
Table 1 - Demographic, Clinical and Laboratory Features of Dermatomyositis Patients and Healthy Individuals.
Parameters DM (n=35) Control (n=48) P
Age (years) 33.3±7.6 33.2±6.5 0.951
White ethnicity 26 (74.3) 34 (70.8) 0.807
Body mass index (kg/m2) 24.5±3.2 24.3±2.6 0.872
Weight (kg) 63.5±9.3 63.7±7.4 0.914
Socioeconomic status 31 (81.6) 46 (95.8) 0.586
Age at disease onset (years) 28.4±9.0 - -
Duration: diagnosis - symptoms (months) 5 (2-18) - -
Disease duration (years) 1.0 (0-6.0) - -
Creatine phosphokinase (U/L) 124 (86-458) 98 (72-122) 0.011
Aldolase (U/L) 6.3 (4.0-11.0) 3.4 (2.8-3.4) o0.001
Lactic dehydrogenase (U/L) 423 (654-715) 322 (293-385) 0.001
Alanine aminotransferase (U/L) 22 (13-51) 15 (12-20) 0.003
Aspartate aminotransferase (U/L) 19 (16-71) 19 (16-21) 0.001
MMT-8 score (0-80) 76 (70-80) - -
HAQ score (0.00-3.00) 0.86 (0.00-0.71) - -
Patient VAS (0-10) 3 (0-5) - -
Physician VAS (0-10) 4 (0-5) - -
MYOACT 0 (0-1) - -
Prednisolone -
Current use 23 (65.7) - -
Total cumulative dose (g)* 15.40 (5.90-27.69)
Antimalarial 8 (22.9) - -
IS/IM**
None 17 (48.6) - -
One 12 (34.3) - -
Azathioprine 6 (17.1)
Methotrexate 3 (8.6)
Cyclosporine 2 (5.7)
Cyclophosphamide 1 (2.8)
Two 6 (17.1) - -
Methotrexate + azathioprine 1 (2.8)
Methotrexate + leflunomide 1 (2.8)
Methotrexate + cyclosporine 1 (2.8)
Methotrexate + IVIg 1 (2.8)
Cyclosporine + azathioprine 1 (2.8)
Mycophenolate mofetil + rituximab 1 (2.8)
Results expressed as percentages (%), means ± standard deviation, or medians (25th - 75th interquartile range).
DM: dermatomyositis; IS: immunosuppressive drugs; IM: immunomodulatory drugs; IVIg: intravenous human immunoglobulin; MYOACT: myositis disease
activity assessment visual analogue scales.
* Since disease symptoms began; ** Azathioprine (2-3 mg/kg/day), methotrexate (15-25 mg/week), cyclosporine (1.5-2.5 mg/kg/day), mycophenolate
mofetil (2-3 g/day), rituximab [1 g, intravenous, at baseline and after one month (first cycle) and this schema was repeated after six months],
cyclophosphamide (0.8 g/m2 body surface), leflunomide (20 mg/day) and/or intravenous human immunoglobulin (2 g/kg, 1x/day, two consecutive days).
Table 2 - Metabolic Syndrome and Laboratory Parameters of Patients with Dermatomyositis and Healthy Individuals.
Parameters DM (n=35) Control (n=48) P
Metabolic syndrome 12 (34.3) 3 (6.3) 0.001
Abdominal circumference (cm) 88.6±10.1 78.9±9.0 o0.001
X80 cm 26 (74.3) 22 (45.8) 0.013
Systemic arterial hypertension 3 (8.6) 1 (2.1) 0.305
Fasting blood glucose (mg/dL) 81 (76-89) 79 (70-84) 0.157
X100 mg/dL 5 (14.3) 1 (2.1) 0.078
Total cholesterol level (mg/dL) 175.2±36.8 185.4±31.5 0.190
LDL cholesterol level (mg/dL) 103.2±32.1 107.03±27.0 0.540
HDL cholesterol level (mg/dL) 48 (42-63) 55 (52-65) 0.017
p50 (mg/dL) 18 (51.4) 7 (14.6) 0.001
Triglyceride level (mg/dL) 83 (61-180) 82 (64-109) 0.017
X150 (mg/dL) 13 (37.1) 4 (8.3) 0.002
Insulin (U/L) 13.0 (9.3-19.5) 7.5 (5.4-12.1) o0.001
Adiponectin (ng/mL) 87.3 (56.1-115.8) 58.8 (39.5-75.8) 0.010
Leptin (ng/mL) 7.9 (0.7-13.6) 14.8 (7.9-22.1) 0.004
Resistin (pg/mL) 100 (80-167) 89 (70-112) 0.049
Results expressed as percentages (%) or medians [25th - 75th interquartile range]. CVD: cardiovascular disease; DM: dermatomyositis; HDL: high-density
cholesterol; LDL: low-density cholesterol.
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those of aldolase (rho=-0.502; p=0.008), triglycerides (rho=
-0.448; p=0.017), aspartate aminotransferase (rho=-0.570;
p=0.002) and alanine aminotransferase (rho=-0.582; p=0.001).
Importantly, these cytokines were not correlated with other
parameters.
A comparison of DM patients with (n=12) or without
(n=23) MetS revealed that patients with MetS were sig-
nificantly older (Table 3).
The distributions of ethnicity, household income status,
age at disease onset, duration between diagnosis and
Table 3 - Comparison of DM Patients with and Without Metabolic Syndrome.
Parameters MetS (+) (n=12) MetS (-) (n=23) P
Age (years) 36.7±5.6 31.5±8.0 0.035
White ethnicity 7 (58.3) 19 (82.6) 0.220
Socioeconomic status 12 (100.0) 19 (82.6) 0.536
Age at disease onset (years) 31.0±10.0 27.1±8.3 0.260
Duration: diagnosis - symptoms (months) 4 (1-14) 5 (3-18) 0.381
Disease duration (years) 0 (0-9) 2 (0-6) 0.362
Body mass index (kg/m2) 25.0±2.6 24.2±3.5 0.511
Weight (kg) 63.6±9.7 63.4±9.2 0.938
Cutaneous manifestations
Heliotrope 10 (83.3) 20 (87.0) 1.000
Gottron’s signal 12 (100.0) 21 (91.3) 0.536
‘‘V’’ sign 6 (50.0) 3 (13.0) 0.038
‘‘Shawl’’ sign 5 (41.7) 1 (4.3) 0.012
Lipodystrophy 0 0 1.000
Calcinosis 0 0 1.000
MMT-8 score (0-80) 66 (60-76) 80 (74-80) 0.002
HAQ score (0.00-3.00) 1.15 (0.00-2.68) 0.57 (0.00-1.71) 0.172
Patient VAS (0-10) 6 (4-7) 2 (0-5) 0.001
Physician VAS (0-10) 6 (4-7) 2 (0-5) 0.011
MYOACT 0 (0-4) 0 (0-0) 0.344
Creatine phosphokinase (U/L) 122 (71-1447) 130 (84-232) 0.817
Aldolase (U/L) 6.9 (5.3-31.4) 5.7 (3.8-10.3) 0.292
Lactic dehydrogenase (U/L) 659 (425-1170) 372 (282-476) 0.010
Alanine aminotransferase (U/L) 57 (65-143) 20 (16-32) 0.028
Aspartate aminotransferase (U/L) 56 (22-96) 19 (19-30) 0.031
Prednisolone
Current use 9 (75.0) 14 (60.9) 0.476
Cumulative dose* (g) 7.1 (1.6-23.0) 15.6 (11.0-30.4) 0.156
Antimalarials 2 (16.7) 6 (26.1) 0.685
IS/IM**
None 9 (75.0) 9 (39.1) 0.075
One 2 (16.7) 10 (43.5) 0.149
Two 1 (8.3) 4 (17.4) 0.640
Systemic arterial hypertension 3 (25.0) 0 -
Abdominal circumference (cm) 92.3±9.7 86.5±9.9 0.112
X80 cm 10 (83.3) 16 (69.6) 0.450
Diabetes mellitus 1 (8.3) 0 -
Ischaemic stroke 0 0 -
Myocardial infarction 0 0 -
Hypothyroidism 2 (16.7) 1 (4.3) 0.266
Sedentary lifestyle 1 (8.3) 2 (8.7) 1.000
Food habit alterations 1 (8.3) 1 (4.3) 1.000
Alcohol consumption 0 0 -
Tobacco 0 0 -
Family history of CVD 1 (8.3) 0 -
Fasting blood glucose (mg/dL) 82 (65-144) 80 (74-85) 0.526
X100 mg/dL 4 (33.3) 1 (4.3) 0.038
Total cholesterol level (mg/dL) 179 (145-212) 165 (144-191) 0.668
LDL cholesterol level (mg/dL) 106.8±33.8 101.3±31.8 0.652
HDL cholesterol level (mg/dL) 39.2±11.0 59.3±18.2 o0.001
p50 (mg/dL) 11 (91.7) 7 (30.4) 0.001
Triglycerides level (mg/dL) 160 (99-241) 80 (60-136) 0.016
X150 (mg/dL) 9 (75.0) 4 (17.4) 0.002
Insulin (U/L) 16.5 (9.4-30.0) 12.3 (6.8-18.2) 0.321
Adiponectin (ng/mL) 74.8 (39.3-125.0) 95.1 (54.0-116.3) 0.349
Leptin (ng/mL) 4.3 (39.3-125.1) 8.9 (0.7-14.7) 0.709
Resistin (pg/mL) 204 (86-292) 92 (76-123) 0.077
Results expressed as percentages (%), means ± standard deviation, or medians (25th - 75th interquartile range).
CVD: cardiovascular disease; DM: dermatomyositis; HDL: high-density cholesterol; IS: immunosuppressive drugs; IM: immunomodulatory drugs;
LDL: low-density cholesterol; MYOACT: myositis disease activity assessment visual analogue scales.
* Since disease symptoms began; * Azathioprine (2-3 mg/kg/day), methotrexate (15-25 mg/week), cyclosporine (1.5-2.5 mg/kg/day), mycophenolate
mofetil (2-3 g/day), rituximab [1 g, intravenous, at baseline and after one month (first cycle) and this schema was repeated after six months],
cyclophosphamide (0.8 g/m2 body surface), leflunomide (20 mg/day) and/or intravenous human immunoglobulin (2 g/kg, 1x/day, two consecutive days).
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symptoms, disease duration, BMI, weight, treatment (corti-
costeroid, immunosuppressives, immunomodulatory and/or
antimalarial) and comorbidities were similar in DM patients
with or without MetS.
The heliotrope and Gottron’s signal distributions were also
similar in both groups in contrast to the ‘‘V’’ sign and
‘‘shawl’’ sign, which were more frequent in the group with
MetS. In this group, the disease status parameters were also
increased, with the exception of the HAQ and MYOACT
scores, which were similar.
The insulin and cytokine (adiponectin, leptin and resistin)
parameters were also comparable between DM patients with
and without MetS.
’ DISCUSSION
The present study revealed an increased prevalence of
MetS in young adult female DM patients. Moreover, higher
serum levels of adiponectin and resistin associated with
lower leptin levels were observed in DM patients with MetS.
Importantly, the presence of MetS was associated with age
and current disease status parameters.
A great advantage of the present study was that it eval-
uated young premenopausal female patients with well-
defined DM. Furthermore, MetS was defined according to
current criteria (22), which are now accepted worldwide.
Previous studies have reported a high prevalence of MetS
in several rheumatic diseases that ranged from 14 to 62.8%
(13,14,24,25). However, only two of these studies analysed
the prevalence of MetS in idiopathic inflammatory myopa-
thies (13,14)], and both used the ATP III criteria (4). These
studies identified MetS in 41.7% and 45.7% of patients with
DM and PM, respectively (13,14). However, it should be
emphasized that these studies evaluated both genders and
included postmenopausal women because they had a large
range of ages. In addition, the patients’ BMIs were not
matched with control groups, which could have contributed
to the high frequency of MetS in these samples.
Another important point in the present study was the
exclusion of all possible confounding parameters that could
have interfered with our analysis. However, we observed a
high frequency of MetS in DM patients (34.3%) compared to
healthy individuals (6.3%). Although the patient group was
BMI-matched to the healthy individual group, we observed
that the former had a larger waist circumference, which
seemed to be the most important contributing factor to MetS
in these patients.
Concerning comorbidities, a low prevalence of risk factors
for CVD was observed herein in contrast to a previous study
(13), which could be explained by the inclusion of young
adults with a short time of disease duration.
In the present study, we observed a high prevalence of
dyslipidaemia in our patients, similar to previous studies
(13,26,27). Of note, this dyslipidaemia may be correlated
with disease activity.
A further analysis of DM patients revealed higher serum
levels of adiponectin and resistin in contrast to lower serum
levels of leptin. Adiponectin, which is a hormone that is
abundantly secreted by adipocytes under normal conditions,
has anti-diabetic, anti-inflammatory and anti-atherogenic
properties (6,28,29). However, this cytokine can be induced
in skeletal muscle after an inflammatory condition or
metabolic/oxidative stress (30-32). In this regard, the
higher serum adiponectin levels observed in DM patients
could be a protective mechanism to counterbalance the
chronic, systemic, inflammatory and immunological pro-
cesses of this disease.
Interestingly, the adiponectin levels in DM patients were
associated with their total cholesterol and LDL cholesterol
levels but not with other parameters, including insulinaemia
and classical MetS. In this regard, waist circumference, which
is related to visceral obesity, was significantly increased in
DM patients. However, it was not associated with adipo-
nectin levels. Therefore, the high rate of adiponectinaemia
could not be explained by possible altered fat mass or
distribution. Moreover, the corticosteroid therapy did not
appear to have an effect on adiponectin values because the
groups received similar corticosteroid doses.
In contrast to adiponectin, resistin is considered a pro-
inflammatory protein with atherogenic effects and is asso-
ciated with peripheral insulin resistance (30,33). A previous
study showed that high serum resistin levels in patients with
inflammatory myopathies (DM and other myositis) were
associated with inflammation, muscle damage and an
increased global disease activity index (12). These authors
and others showed that resistin gene expression in muscle
tissue was significantly increased in patients compared to
controls (12,34). Thus, resistin could play a potential role in
the pathogenesis of inflammatory myopathies. This possibi-
lity was confirmed in our study because resistin was also
increased in DM patients, but no correlation was detected
with clinical and laboratory parameters.
In contrast, we observed low serum levels of leptin in our
patients with DM. Leptin is a cytokine that is produced
mainly by adipocytes and participates in a wide variety of
physiological processes, including modulating immune
responses by acting as a pro-inflammatory cytokine (35).
Paradoxically, in the present study, leptin was negatively
associated with serum levels of muscle enzymes and
triglycerides.
The comparison of DM patients with and without
MetS revealed that this condition is related to ageing,
similar to a previous study (in a univariate analysis) (13).
Moreover, MetS in DM patients was not correlated with
corticosteroid use, reinforcing the data of the previous
study (13).
Similarly, the presence of cutaneous lesions (‘‘V’’ sign and
‘‘shawl’’ sign) was more frequently observed in patients with
MetS, which should be confirmed in other studies.
The present study had some limitations. The cross-
sectional design, rather than a longitudinal analysis, limited
the evaluation of MetS parameters and variation in adipo-
cytokines. In addition, we must consider the possible
inclusion of a more severe disease due to the characteristics
of our tertiary care centre.
In summary, a high frequency of MetS was observed
in young DM patients, which was associated with high
adiponectin and resistin levels and low leptin levels. In
addition, MetS occurred predominantly due to the presence
of abdominal abnormalities and was associated with ageing
and disease activity status. These data reinforce the role of
adipokines and provide a better understanding of their
mechanisms and regulatory pathways.
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